{"id":31256,"date":"2014-09-16T11:37:52","date_gmt":"2014-09-16T15:37:52","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=31256"},"modified":"2014-09-16T11:37:52","modified_gmt":"2014-09-16T15:37:52","slug":"regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256","title":{"rendered":"Regeneron Pharmaceuticals Inc (NASDAQ:REGN)\u2019s EYLEA Gets FDA Breakthrough Designation"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 09\/16\/2014 (wallstreetpr) \u2013 <strong>Regeneron Pharmaceuticals Inc (NASDAQ:REGN)<\/strong> announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to <a href=\"http:\/\/www.prnewswire.com\/news-releases\/eylea-aflibercept-injection-receives-fda-breakthrough-therapy-designation-for-diabetic-retinopathy-in-patients-with-diabetic-macular-edema-275256871.html\" target=\"_blank\">EYLEA<\/a>. The drug targets patients with diabetic macular edema (DME) for the treatment of diabetic retinopathy. The Breakthrough Therapy designation was triggered by the positive results obtained from two late-stage trials of the drug. EYLEA promises hope for millions of patients in the U.S. and around the world.<\/p>\n<p style=\"text-align: justify;\">EYLEA underwent two Phase 3 clinical trials that were identified as VIVID-DME and VISTA-DME. The trials returned compelling statistical results in patients with DME following two years of treatment. The results triggered the Breakthrough Therapy designation as the regulator noted significant potential in the drug for the treatment of treatment of diabetic retinopathy.<\/p>\n<p style=\"text-align: justify;\"><strong>Benefits of Breakthrough designation<\/strong><\/p>\n<p style=\"text-align: justify;\">The Breakthrough Therapy designation earns Regeneron Pharmaceuticals Inc (NASDAQ:REGN) special treatment before the regulator in the development of EYLEA for the treatment of the target disease. Such special treatments include an expedited review of EYLEA. The designation will also earn Regeneron (NASDAQ:REGN) a number of fast track features in the development of EYLEA. A drug must demonstrate credible evidence of ability to handle the targeted condition over the existing treatments, or placebo where no other treatment is available, to earn Breakthrough designation.<\/p>\n<p style=\"text-align: justify;\">Regeneron Pharmaceuticals Inc (NASDAQ:REGN) expects to work closely with the regulator to bring EYLEA to patients suffering from diabetic retinopathy. Officials at the company cited that there are currently no FDA-approved treatments for diabetic retinopathy, yet millions of people in the U.S. and elsewhere are faced with the problem.<\/p>\n<p style=\"text-align: justify;\">EYLEA already carries U.S. and EU approvals for the treatment of DME, wet age-related macular degeneration (AMD), and macular edema following central retinal vein occlusion (CRVO). EYLEA\u2019s approval in these categories has also been secured in other countries beyond the U.S. and EU. Regeneron (NASDAQ:REGN) said it had also submitted for approval of EYLEA for treatment of macular edema following branch retinal vein occlusion (BRVO) in the U.S. and EU.<\/p>\n<p style=\"text-align: justify;\"><strong>Inspiring performance<\/strong><\/p>\n<p style=\"text-align: justify;\">Regeneron Pharmaceuticals Inc (NASDAQ:REGN)\u2019s financial performance in the most recent quarter was source of inspiration as the company breached both earnings and revenue expectations. The company reported revenue of $666 million, ahead of the estimate of $647.99 million in 2Q2014.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 09\/16\/2014 (wallstreetpr) \u2013 Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to EYLEA. The drug [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":31260,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[4507,7251,4506],"stock_ticker":[],"class_list":["post-31256","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqregn","tag-regeneron-pharmaceuticals-inc","tag-regeneron-pharmaceuticals-inc-nasdaqregn","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Regeneron Pharmaceuticals Inc (NASDAQ:REGN)\u2019s EYLEA Gets FDA Breakthrough Designation - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regeneron Pharmaceuticals Inc (NASDAQ:REGN)\u2019s EYLEA Gets FDA Breakthrough Designation - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/16\/2014 (wallstreetpr) \u2013 Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to EYLEA. The drug [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-16T15:37:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/REGE.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"164\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Brendan Byrne\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Brendan Byrne\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256\"},\"author\":{\"name\":\"Brendan Byrne\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\"},\"headline\":\"Regeneron Pharmaceuticals Inc (NASDAQ:REGN)\u2019s EYLEA Gets FDA Breakthrough Designation\",\"datePublished\":\"2014-09-16T15:37:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256\"},\"wordCount\":390,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/REGE.jpg\",\"keywords\":[\"NASDAQ:REGN\",\"Regeneron Pharmaceuticals Inc\",\"Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256\",\"name\":\"Regeneron Pharmaceuticals Inc (NASDAQ:REGN)\u2019s EYLEA Gets FDA Breakthrough Designation - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/REGE.jpg\",\"datePublished\":\"2014-09-16T15:37:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/REGE.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/REGE.jpg\",\"width\":300,\"height\":164},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regeneron Pharmaceuticals Inc (NASDAQ:REGN)\u2019s EYLEA Gets FDA Breakthrough Designation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\",\"name\":\"Brendan Byrne\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"caption\":\"Brendan Byrne\"},\"description\":\"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Regeneron Pharmaceuticals Inc (NASDAQ:REGN)\u2019s EYLEA Gets FDA Breakthrough Designation - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256","og_locale":"en_US","og_type":"article","og_title":"Regeneron Pharmaceuticals Inc (NASDAQ:REGN)\u2019s EYLEA Gets FDA Breakthrough Designation - Wall Street PR","og_description":"Boston, MA 09\/16\/2014 (wallstreetpr) \u2013 Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to EYLEA. The drug [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-16T15:37:52+00:00","og_image":[{"width":300,"height":164,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/REGE.jpg","type":"image\/jpeg"}],"author":"Brendan Byrne","twitter_misc":{"Written by":"Brendan Byrne","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256"},"author":{"name":"Brendan Byrne","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511"},"headline":"Regeneron Pharmaceuticals Inc (NASDAQ:REGN)\u2019s EYLEA Gets FDA Breakthrough Designation","datePublished":"2014-09-16T15:37:52+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256"},"wordCount":390,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/REGE.jpg","keywords":["NASDAQ:REGN","Regeneron Pharmaceuticals Inc","Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256","url":"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256","name":"Regeneron Pharmaceuticals Inc (NASDAQ:REGN)\u2019s EYLEA Gets FDA Breakthrough Designation - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/REGE.jpg","datePublished":"2014-09-16T15:37:52+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/REGE.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/REGE.jpg","width":300,"height":164},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/regeneron-pharmaceuticals-inc-nasdaqregns-eylea-gets-fda-breakthrough-designation-31256#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Regeneron Pharmaceuticals Inc (NASDAQ:REGN)\u2019s EYLEA Gets FDA Breakthrough Designation"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511","name":"Brendan Byrne","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","caption":"Brendan Byrne"},"description":"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/31256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=31256"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/31256\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/31260"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=31256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=31256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=31256"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=31256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}